JNJ | Weekly | Haru Insights

Johnson & Johnson (JNJ) secured a $5.5 billion talc settlement in July 2026, marking a pivotal step in resolving one of its longest-running legal liabilities—though over 100,000 lawsuits remain unresolved and a recent Louisiana jury verdict upheld liability in a mesothelioma case, signaling that litigation risk persists.
JNJ announced a $300 million strategic investment in Protagonist Therapeutics, a biotech with a pivotal FDA decision expected in August 2026 on rusfertide for polycythemia vera—signaling a high-conviction bet on next-gen autoimmune and rare cancer therapies.

JNJ’s oncology segment is now a powerhouse, driving 16.9% H1 2026 revenue growth with blockbuster drugs like Carvykti and Darzalex, cementing its leadership in high-margin, innovation-led pharmaceuticals.
The $300 million stake in Protagonist Therapeutics reflects a bold, venture-like strategy that could unlock massive upside if rusfertide gains FDA approval—transforming JNJ into a hidden biotech growth engine.
Despite legal headwinds, JNJ stock has surged 59.27% over the past year and continues to outperform benchmarks, proving market confidence in its innovation pipeline and durable cash flow despite high valuation.
JNJ is playing a central role in U.S. medical manufacturing reshoring, with direct partnerships and supply chain investments that align it with national policy shifts and reduce geopolitical supply risks.
The company’s diversified pipeline and sustained R&D momentum signal resilience—even amid legal and patent challenges—underscoring long-term strategic depth.

Johnson & Johnson (JNJ)[Tv]